
The MHRA expanded Joenja’s UK authorization to eligible children aged 4 to 11, with patient access expected in February 2027.
Pharming said the UK medicines regulator has approved Joenja for children aged 4 to 11 with activated PI3K delta syndrome (APDS), provided they weigh at least 27 kg. The company said it is the first treatment approved in the UK specifically for children with APDS.
The expanded authorization includes twice-daily doses of 40 mg and 50 mg. Joenja was previously authorized in the UK for eligible adults and adolescents aged 12 and older.
Pharming expects the treatment to become available to patients covered by the expanded indication in February 2027. The company said the MHRA’s decision was supported by its pediatric clinical program and additional safety and pharmacology assessments.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.